Status:
RECRUITING
A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
Lead Sponsor:
Pfizer
Conditions:
Severe Alopecia Areata
Eligibility:
All Genders
12+ years
Brief Summary
The purpose of this observation study is to learn about the safety and effects of the study medicine (called Litfulo) for the potential treatment of Severe Alopecia Areata.
Detailed Description
To evaluate the safety of Litfulo Capsule after marketing, with regard to the following clauses in routine clinical practice. * Adverse Events (AEs)/ Adverse Drug Reactions (ADRs) * Unexpected Advers...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with severe alopecia areata who have been determined to start treatment with Litfulo Capsule according to the approved indications of the medicinal product Treatment of severe alopecia areata in adults and adolescents 12 years or older Evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s)/legal guardian, if applicable, have been informed of all pertinent aspects of the study
Exclusion
Key Trial Info
Start Date :
August 27 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 23 2030
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT07152119
Start Date
August 27 2025
End Date
March 23 2030
Last Update
November 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer, Inc
Seoul, South Korea